Metagenomi Therapeutics reports $21.13 million net loss

Metagenomi Therapeutics (MGX) filed a 10-Q with the SEC on Nov 10, 2026, 4:09 pm ET. Source: the filing on SEC EDGAR.

Quarterly report, 4 new risk factors

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

What changed since last quarter

4 new risk factors · 4 removed · 1 new legal mention

Compared with the 10-Q for the period ended Jun 30, 2026.

New risk factors (4)

There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not…
Amongst private companies, Tessera Therapeutics, Inc. is developing recombinase DNA and RNA gene writers. Arbor Biotechnologies, Inc. and Mammoth Biosciences, Inc. are actively searching for novel genome editing components and have reported the discovery of new DNA-cutting enzymes. Other companies such as Epicrispr…
On December 19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs: the Global Benchmark for Efficient Drug Pricing Model ("GLOBE") for Medicare Part B and the Guarding U.S. Medicare Against Rising Drug Costs ("GUARD") model for… +1 more paragraph
Although the EU GDPR and the UK GDPR currently impose substantially similar obligations, it is possible that over time the UK GDPR could become less aligned with the EU GDPR. For example, the UK Data (Use and Access) Act 2025 ("UK Act") has amended the UK's data protection regime, further differentiating it from the…

Removed risk factors (4)

There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not…
In addition, Tessera Therapeutics, Inc. has announced their work in recombinase DNA and RNA gene writers, although, as a privately-held company, less is known publicly about their science or portfolio. Other companies such as nChroma Bio and Tune Therapeutics, Inc. are focused on epigenetic editing. In addition, we… +1 more paragraph
On December 19, 2025, CMS released two proposed rules that would incorporate MFN pricing principles into federal reimbursement for prescription drugs. The first proposal, the Global Benchmark for Efficient Drug Pricing Model ("GLOBE") for Medicare Part B, would require manufacturers of specified single source drugs…
Although the EU GDPR and the UK GDPR currently impose substantially similar obligations, it is possible that over time the UK GDPR could become less aligned with the EU GDPR. The UK Government has introduced a Data Protection and Digital Information Bill to reform the UK data protection legal framework which failed…

New legal mentions (1)

On October 21, 2026, counsel for lead plaintiff and for defendants participated in a mediation of this matter, and the parties have reached an agreement in principle to settle the class claims, subject to court approval, for $7.5 million, a significant portion of which will be funded by insurance proceeds.